# Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer

> **NCT03409198** · PHASE2 · COMPLETED · sponsor: **Oslo University Hospital** · enrollment: 82 (actual)

## Conditions studied

- Breast Cancer
- Hormone Receptor Positive Tumor
- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Nivolumab
- **DRUG:** Pegylated liposomal doxorubicin
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT03409198
- **Lead sponsor:** Oslo University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-21
- **Primary completion:** 2022-05-11
- **Final completion:** 2022-05-11
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2024-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03409198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03409198, "Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT03409198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*